All In Biotech

NDA 215064 · Chiesi

Filsuvez

Birch Triterpenes · Topical

NovelPriority reviewOrphan

CDER novel approval, Dec 18, 2023: To treat wounds associated with dystrophic and junctional epidermolysis bullosa

Last checked: Nov 20, 2026Latest source record: Dec 18, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2023

Dec 18, 2023

Approved uses

1

Original approval plus efficacy supplements

Registered trials

1

0 Phase 3, 0 recruiting

FAERS reports

276

54 serious, 13 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 24, 2026.

FILSUVEZ is indicated for the treatment of wounds associated with dystrophic and junctional epidermolysis bullosa (EB) in adult and pediatric patients 6 months of age and older. FILSUVEZ topical gel is indicated for the treatment of wounds associated with dystrophic and junctional epidermolysis bullosa in adult and pediatric patients 6 months of age and older. ( 1 )

Mechanism: The mechanism of action of FILSUVEZ in the treatment of wounds associated with epidermolysis bullosa is unknown.

Therapeutic areas: Dermatology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 18, 2023 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelReviewLetter
1 products under this application
  • FILSUVEZ · BIRCH TRITERPENES 10% · GEL, TOPICAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Birch Triterpenes" as an intervention, any sponsor and status, largest first.

All 1 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • wound complication43
  • wound41
  • product dose omission issue40
  • product use issue38
  • wrong technique in product usage process26
  • drug ineffective25
  • off label use24
  • product administration interrupted24
  • treatment noncompliance18
  • blister17
  • pruritus15
  • wound secretion15

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
202453
2025102
2026121

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Filsuvez (Birch Bark Extract)

2024 spending

$1.6M

Beneficiaries

11

28 claims

Per beneficiary

$143,052

$78.65 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$0
2024$1,573,576

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 4 on PubMed

Sponsor: Chiesi

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.